INmune Bio, Inc. (INMB)
INmune Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
INmune Bio, Inc. (INMB) is a Biotechnology company based in US with a market capitalization of $52.4M. Revenue grew 257.1% year-over-year and free cash flow was negative at -$23.6M. This page tracks INMB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 13 employees · IPO Feb 4, 2019
Valuation
Valuation & price
$1.55as of May 17, 2026· -50.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.23
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$52.4M
Market cap
257.1%
Revenue growth (YoY)
100.0%
Gross margin
-$23.6M
Free cash flow (USD)
-$23.7M
Net debt
Net cash position
33.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 1, 2026Filing
Warrant Inducement Offer
- 8-K eventJun 23, 2026Filing
Regulatory Meeting Update
- 8-K eventJun 17, 2026Filing
Stock Incentive Plan Amended
- 8-K eventJun 2, 2026Filing
Phase 2 Trial Results
- 8-K eventMay 14, 2026Filing
FDA Fast Track Designation
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventMay 5, 2026Filing
Agreement Amendment
Questions
Frequently asked questions
What is INmune Bio, Inc.'s market cap?
INmune Bio, Inc. (INMB) has a market capitalization of $52.4M.
What is INMB's P/E ratio?
A meaningful P/E ratio is not available for INMB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is INMB's price-to-book (P/B) ratio?
INMB trades at 2.23 times book value per share.
Are insiders buying INMB stock?
SEC Form 4 filings show no open-market insider buys at INmune Bio, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.